SCHEMBL4522899

SCHEMBL4522899

Cc1ccccc1CN1CCN(Cc2ccncc2)C1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
CLPP Q16740 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MAPT P10636 2/20 0.52
TSHR P16473 2/20 0.52
P2RX7 Q99572 3/20 0.50
PRMT5 O14744 2/20 0.47
WDR77 Q9BQA1 2/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
ALDH1A1 P00352 2/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
LMNA P02545 1/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C19 P33261 2/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4511636 0.88 KDM4E (0.66) KMT2AMEN1SMN1; SMN2CLPPKDM4E
SCHEMBL4512688 0.86 KMT2A (0.65) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL4526855 0.85 CLPP (0.57) KMT2AMEN1SMN1; SMN2CLPPKDM4E
SCHEMBL4513866 0.83 KDM4E (0.57) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL4519320 0.83 KMT2A (0.55) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL4523295 0.82 CYP1A2 (0.64) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL4515572 0.80 MAPT (0.67) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL4525369 0.80 MEN1 (0.55) KMT2AMEN1SMN1; SMN2CLPPKDM4E
SCHEMBL4513815 0.80 KDM4E (0.60) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL4507401 0.79 TSHR (0.69) KMT2AMEN1SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 KMT2A 2379/4885MEN1 1254/4885SMN1; SMN2 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.